Welcome to our dedicated page for Xcelerate news (Ticker: XCRT), a resource for investors and traders seeking the latest updates and insights on Xcelerate stock.
Xcelerate, Inc. (XCRT) publishes frequent updates on its progress in medical technology, AI-assisted virtual health and consumer health and beauty products. The news flow provides insight into how the company is executing its business plan, adjusting its portfolio of assets and advancing its intellectual property.
Recent press releases describe Xcelerate’s decision to sell its majority interest in the ESN Group of companies in an all-cash transaction to Noble Labs Holdings, LLC, with the stated goal of refocusing on its original mission of implementing AI-aided medical technology and virtual health care in Africa through its majority-owned subsidiary, AfiyaSasa Africa, LLC. Other announcements highlight renewed emphasis on the AfiyaSasa project, including plans to launch an AI-assisted patient portal in Tanzania and to acquire a clinical care setting in which the technology can be trialed, tested and applied.
News items also cover developments in Xcelerate’s medical device patents, such as the commencement of the nationalization process for PCT international patent applications related to a Surgical Tool with Targeting Guidance that introduces a "first-person view" to the surgical theatre. Additional releases discuss corporate matters, including changes of auditors, re-audits of financial statements, filings of annual and semi-annual reports, amendments to registration statements, and the engagement of an investment bank to assist with capital raising and potential up-listing to a national exchange.
Investors and observers can use the XCRT news feed on this page to follow company statements on AI-driven healthcare initiatives, patent filings, divestitures, funding arrangements and shareholder communications, all in one place.
Xcelerate, Inc. announced the filing of its 2023 Annual Report, reporting audited financial results for the year. The company achieved its first revenue year in history, marking significant milestones and progress towards growth. Revenues from the majority interest in ESN Group are set to increase in 2024 due to new contracts.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Xcelerate (OTCQB:XCRT) has filed two utility patent applications (18/187,352 and 18/189,441) along with corresponding PCT applications (PCT/US2023/015755 and PCT/US2023/016194), building on its prior application from March 24, 2022. The patents focus on surgical tools with targeting guidance and reflect the company's mission to integrate engineering advancements into clinical care. CEO Michael O'Shea highlighted the importance of parallel development and intellectual property protection in their surgical device lines. The company is advancing its In-Tool-Optics prototypes that enhance surgical precision by offering a first-person view. Three product lines are being developed: ITO-Responder for emergency use, ITO-Clinic for hospital environments, and ITO-Infirmary for retrofitting existing tools. This initiative aims to improve efficiency in surgical procedures.